A Phase 2 Open-label Randomized, Controlled Trial of CS-1008 in Combination With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Oxaliplatin Based Regimen.
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2012
At a glance
- Drugs Irinotecan; Tigatuzumab
- Indications Colorectal cancer
- Focus Therapeutic Use
- 18 Jul 2012 Planned number of patients changed from 80 to 92 as reported by EudraCT.
- 18 Jul 2012 Company added in the association field as reported by EudraCT.
- 30 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.